Treatment of tuberculosis: present status and future prospects

被引：0

作者：

Onyebujoh, P ^{[1
]}

Zumla, A

Ribeiro, I

Rustomjee, R

Mwaba, P

Gomes, M

Grange, JM

机构：

[1] WHO, World Bank, UNICEF, UNDP,Special Programme Res & Training Trop Dis,Ct, Geneva, Switzerland

[2] UCL, Windeyer Inst Med Sci, Ctr Infect Dis & Int Hlth, London, England

[3] MRC, TB Res Unit, Clin & Biomed Res Unit, Durban, South Africa

[4] Univ Zambia, Sch Med, Lusaka, Zambia

来源：

BULLETIN OF THE WORLD HEALTH ORGANIZATION | 2005年 / 83卷 / 11期

关键词：

tuberculosis; multidrug-resistant/drug therapy; antitubercular agents/administration and dosage/adverse effects; directly observed therapy; drug therapy/trends; drug combinations; quinolones; quinoline; nitroimidazoles; quinolizines; HIV infections/drug therapy; evaluation studies;

D O I：

暂无

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

Over recent years, tuberculosis (TB) and disease caused by human immunodeficiency virus (HIV) have merged in a synergistic pandemic. The number of new cases of TB is stabilizing and declining, except in countries with a high prevalence of HIV infection. In these countries, where HIV is driving an increase in the TB burden, the capacity of the current tools and strategies to reduce the burden has been exceeded. This paper summarizes the current status of TB management and describes recent thinking and strategy adjustments required for the control of TB in settings of high HIV prevalence. We review the information on anti-TB drugs that is available in the public domain and highlight the need for continued and concerted efforts (including financial, human and infrastructural investments) for the development of new strategies and anti-TB agents.

引用

页码：857 / 865

页数：9

共 49 条

[1] Comparative bioavailability of rifampicin, isoniazid and pyrazinamide from a four drug fixed dose combination with separate formulations at the same dose levels [J].